Cell therapy (Antigen-specific T cells) · Kills target cells, directed at Epstein-Barr virus-associated antigens · developed by Atara Biotherapeutics
Tabelecleucel is an allogeneic, off-the-shelf cytotoxic T-lymphocyte therapy directed against Epstein-Barr virus (EBV) antigens expressed on EBV-infected cells. It binds these antigens and lyses the infected cells. It is studied in EBV-associated lymphomas and malignancies, EBV-associated nasopharyngeal carcinoma, and EBV-positive progressive multiple sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03769467 | Phase 1/2 | Nasopharyngeal Carcinoma | Terminated | ATRA |
| NCT03283826 | Phase 1/2 | Primary Progressive Multiple Sclerosis | Terminated | ATRA |
| NCT01498484 | Phase 2 | EBV-induced Lymphomas | Completed | ATRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EBV-associated MalignanciesEBV-induced LymphomasEpstein-Barr ViraemiaEpstein-Barr Virus InfectionsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Updated Oct 11, 2026. Something wrong or missing? Report it on the ATRA page.
See ATRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ATRA catalysts and pipeline →